The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FE | EGFR (Epidermal Growth Factor Receptor) inhibitors |
| Code | Title | |
|---|---|---|
| L01FE01 | Cetuximab | |
| L01FE02 | Panitumumab | |
| L01FE03 | Necitumumab |
| Active Ingredient | Description | |
|---|---|---|
| Cetuximab |
Cetuximab is a chimeric monoclonal IgG1 antibody that is specifically directed against the epidermal growth factor receptor (EGFR). EGFR signalling pathways are involved in the control of cell survival, cell cycle progression, angiogenesis, cell migration and cellular invasion/metastasis. Cetuximab blocks binding of endogenous EGFR ligands resulting in inhibition of the function of the receptor. |
|
| Panitumumab |
Panitumumab is a recombinant, fully human IgG2 monoclonal antibody that binds with high affinity and specificity to the human EGFR. Panitumumab binds to the ligand binding domain of EGFR and inhibits receptor autophosphorylation induced by all known EGFR ligands. Binding of panitumumab to EGFR results in internalisation of the receptor, inhibition of cell growth, induction of apoptosis, and decreased interleukin 8 and vascular endothelial growth factor production. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ERBITUX Solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| Portrazza Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| VECTIBIX Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
